This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record. Numerical trial results on this page are restricted to the results posted in the ClinicalTrials.gov record; calculations added by Clinical Biostats are labelled as such.
1. Trial at a Glance
This page covers the registry results for A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (NCT04320615), a randomized phase 3 study. The primary outcome is Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4).
| Feature | Registry value |
|---|---|
| ClinicalTrials.gov identifier | NCT04320615 |
| Phase | Phase 3 |
| Condition | COVID-19 Pneumonia |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Enrollment | 452 |
| Arms in the primary outcome | n/a |
| Lead sponsor | Hoffmann-La Roche |
| Results posted | Yes |
2. Clinical Question
Population
Hospitalized patients with severe COVID-19 pneumonia. The primary-outcome population is described as the mITT population: randomized participants who received any amount of study medication, grouped according to their randomized assignment.
Intervention
Tocilizumab (TCZ) alongside standard of care. The registry describes an intravenous infusion dosed at 8 mg/kg, up to a maximum dose of 800 mg, with up to one additional dose permitted if symptoms worsen or show no improvement.
Comparator
A placebo matched to tocilizumab, alongside standard of care. The placebo arm could also receive up to one additional infusion if clinical symptoms worsened or showed no improvement.
Primary question
How did clinical status at Day 28, assessed with a seven-category ordinal scale, compare between randomized groups? The scale ranges from discharged or ready for discharge to death, with intermediate categories describing hospital and respiratory-support status. The numerical group results and comparison are not reported in the registry record.
This is a question about the distribution of clinical status across ordered levels, rather than a single event such as discharge or death. The categories encode increasing levels of clinical support and severity, but the registry record does not state that the primary analysis reduced them to a particular threshold or combined categories. The exact statistical contrast used for the primary outcome is not reported in the registry record.
The trial also lists outcomes concerning improvement, discharge, mechanical ventilation, intensive care, and clinical status at an earlier assessment. Those outcomes provide additional perspectives on the course of illness, but their numerical results are not reported in the registry record. The available record therefore establishes the trial question and measurement framework, but does not permit a numerical assessment of the primary comparison or those secondary outcomes.
3. Trial Design
This was a randomized, double-blind, placebo-controlled, multicenter Phase 3 study with a parallel-group design. Its stated purpose was to evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab compared with matching placebo, both in combination with standard of care, among hospitalized patients with severe COVID-19 pneumonia. The registry lists an enrollment of 452 and the study status as completed.
Random allocation is intended to make treatment groups comparable, on average, with respect to both measured and unmeasured characteristics at the time of assignment. It does not guarantee that every characteristic is balanced in a particular trial. The registry says participants were grouped according to their randomized assignment for the primary-outcome population, which is consistent with preserving the randomized comparison among participants who received study medication.
Double masking means that the trial was designed to keep treatment assignment concealed from more than one group involved in the study. The registry does not identify which roles were masked, or describe procedures for maintaining or breaking the mask. A matching placebo can help reduce differences in care or assessment that might arise if treatment assignment were known, but the registry record does not report whether masking was assessed.
The intervention description specifies an intravenous tocilizumab dose of 8 mg/kg up to a maximum of 800 mg and allows up to one additional dose if symptoms worsen or show no improvement. The placebo description likewise allows up to one additional infusion under that condition. The registry does not report how often additional doses were used. The primary outcome was clinical status at Day 28 on a seven-category ordinal scale. The statistical analysis plan, allocation ratio, sample-size justification, and details of the primary comparison are not reported in the registry record.
4. Participant Flow and Accounting
The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.
Before assignment: 452 participants were randomized in the study. Of the 452 participants enrolled, 14 were randomized but not dosed and therefore discontinued from the study.
Overall Study
| Stage | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm |
|---|---|---|
| STARTED | 144 | 294 |
| COMPLETED | 96 | 190 |
| NOT COMPLETED | 48 | 104 |
Reasons for not completing this period:
| Reason | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm |
|---|---|---|
| Withdrawal by Subject | 4 | 10 |
| Physician Decision | 2 | 0 |
| Other | 2 | 0 |
| Lost to Follow-up | 5 | 23 |
| Death | 35 | 71 |
Analysis population for the primary outcome, as defined in the registry: mITT population: Defined as all randomized participants who received any amount of study medication, with participants grouped according to the treatment assigned at randomization.
5. Baseline Characteristics
The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.
| Characteristic | Unit | Placebo Modified Intent-to-Treat (mITT) Arm | Tocilizumab (TCZ) mITT Arm | Total |
|---|---|---|---|---|
| Participants analysed | 144 | 294 | 438 | |
| Age, Continuous | Years | 60.6 (SD 13.7) | 60.9 (SD 14.6) | 60.8 (SD 14.3) |
| Sex: Female, Male: Female | Participants | 43 | 89 | 132 |
| Sex: Female, Male: Male | Participants | 101 | 205 | 306 |
| Ethnicity (NIH/OMB): Hispanic or Latino | Participants | 47 | 94 | 141 |
| Ethnicity (NIH/OMB): Not Hispanic or Latino | Participants | 86 | 181 | 267 |
| Ethnicity (NIH/OMB): Unknown or Not Reported | Participants | 11 | 19 | 30 |
| Race (NIH/OMB): American Indian or Alaska Native | Participants | 5 | 8 | 13 |
| Race (NIH/OMB): Asian | Participants | 10 | 28 | 38 |
| Race (NIH/OMB): Native Hawaiian or Other Pacific Islander | Participants | 5 | 3 | 8 |
| Race (NIH/OMB): Black or African American | Participants | 26 | 40 | 66 |
| Race (NIH/OMB): White | Participants | 76 | 176 | 252 |
| Race (NIH/OMB): More than one race | Participants | 1 | 0 | 1 |
| Race (NIH/OMB): Unknown or Not Reported | Participants | 21 | 39 | 60 |
6. Primary Endpoint
The registry lists the primary outcome as Clinical Status Assessed Using a 7-Category Ordinal Scale at Day 28 (Week 4), measured over Day 28.
| Element | Registry entry |
|---|---|
| Result type | Number |
| Measure of spread | not applicable |
| Unit | Percentage of Participants |
| Endpoint classification | Binary Endpoint |
The primary endpoint is clinical status assessed at Day 28 using a seven-category ordinal scale. Its categories range from discharged or ready for discharge, through differing levels of hospital care and respiratory support, to death. The endpoint is reported as a percentage of participants, and the registry describes the parameter as a number. The primary-outcome population is the mITT population, defined as randomized participants who received any amount of study medication and analyzed according to their randomized assignment.
An ordinal scale preserves ordering: some categories represent better clinical status than others. It can capture a broad range of outcomes in one measure, including distinctions among levels of hospital care that a simple alive-or-dead measure would not express. It also avoids treating every clinical state as equivalent within a broad binary grouping. As a general statistical consideration, however, ordinal categories do not necessarily represent equal-sized steps in clinical status. Interpretation depends on the analysis and contrast used, which are not reported in the registry record.
The registry describes the measure and its assessment time, but the numerical distribution across categories, the group comparison, and its uncertainty are not reported in the registry record. The endpoint definition alone therefore explains what was intended to be measured, not what the trial found.
7. Why No Re-analysis Is Shown
8. Statistical Interpretation
The registry record describes a completed randomized trial and identifies clinical status at Day 28 as its primary outcome. It does not report the numerical primary-outcome results, the distribution across the seven categories, an effect estimate, or a confidence interval. As a result, the treatment groups' observed clinical status cannot be compared quantitatively from the information reported in the registry record.
This distinction matters because an endpoint definition is not an outcome result. Knowing that the scale ranges from discharge or readiness for discharge to death does not reveal how many participants occupied each category, whether the distributions differed, or how precisely any difference was estimated. No direction or magnitude of the primary treatment effect can be inferred from the trial title, design, enrollment, or endpoint description.
The registry lists secondary outcomes including time to clinical improvement, time to improvement on an ordinal scale, time to hospital discharge or readiness for discharge, mechanical ventilation, ventilator-free days, intensive care stay, and clinical status at Day 14. Numerical results for these outcomes are not reported in the registry record. Their inclusion indicates what else the study set out to assess, but it does not establish findings for any of them.
The record does contain safety-group counts. In the placebo safety-evaluable population, 64 participants are listed with serious adverse events among 143 at risk; in the tocilizumab safety-evaluable population, 116 are listed among 295 at risk. Other adverse events are listed for 29 of 143 placebo participants and 83 of 295 tocilizumab participants. Deaths are listed as 36 and 72, respectively. These figures describe the registry's reported counts and denominators. They do not establish that an event was caused by study treatment, nor do they substitute for the missing primary efficacy results. The record does not provide the information needed to assess comparability of follow-up or to interpret these counts as adjusted treatment effects.
The serious adverse-event terms listed most often include COVID-19 pneumonia at 14.0%, septic shock at 4.9%, COVID-19 at 4.7%, respiratory failure at 4.2%, cardiac arrest at 3.5%, and acute kidney injury at 3.4%. These percentages describe reported terms; the record does not give the group-specific breakdown for each listed term in the information available for this analysis.
Overall, the registry supports a description of the trial design, endpoint, and some safety counts, but not a numerical conclusion about the primary comparison. A valid interpretation of efficacy would require the outcome results and the analysis details that are not reported in the registry record. Absence of those results in the record is not evidence that the groups were the same, or that one group did better.
9. Statistical Methods Explained
What does randomization contribute?
Randomization assigns participants to groups by chance. In general, this helps prevent treatment assignment from being systematically linked to participants' characteristics and supports a fair comparison of outcomes. It balances characteristics only in expectation; chance differences can remain. Randomization does not itself ensure complete follow-up, correct outcome measurement, or an unbiased analysis if participants are excluded in ways related to outcome or assignment.
The registry identifies the study as randomized and says the primary mITT population includes randomized participants who received any amount of study medication, grouped according to assignment at randomization. The record does not report the randomization procedure, allocation concealment details, or whether the primary analysis included all randomized participants regardless of whether they received study medication.
What does double masking contribute?
In general, masking can reduce the chance that knowledge of treatment assignment influences participant behavior, clinical management, or outcome assessment. A placebo matched to the active intervention can support masking by making the study treatments less distinguishable. The registry calls the design double-blind and describes a matching placebo, but does not state which people were masked, how masking was maintained, or whether it was successful. These details are not reported in the registry record.
How should an ordinal endpoint be understood?
An ordinal outcome consists of ordered categories. For this endpoint, the categories represent clinical states ranging from discharge or readiness for discharge to death, with hospital-care and respiratory-support states between them. The ordering is meaningful, but the gaps between adjacent categories need not be equal. Consequently, treating the categories as if they formed a continuous scale requires assumptions that are not established by the endpoint description alone.
Different statistical methods can address an ordinal outcome in different ways. A method may compare the overall distribution, estimate the odds of being in a more favorable category under a model, or define a particular threshold and compare the resulting binary outcome. These approaches answer different questions and can rely on different assumptions. The statistical method and primary contrast used for this trial are not reported in the registry record, so no particular interpretation of an effect estimate can be assigned.
What do estimates and confidence intervals usually convey?
As a general statistical explanation, an effect estimate describes the size and direction of a contrast between groups on a specified scale. A confidence interval expresses the uncertainty associated with that estimate under the method's assumptions. A narrow interval indicates greater precision than a wide interval, but an interval does not address every possible source of bias, measurement error, or model misspecification. No primary effect estimate or confidence interval is reported in the registry record.
A p-value, when reported, measures how incompatible the observed data are with a specified null hypothesis under a statistical model. It is not the probability that the null hypothesis is true, and it does not measure clinical importance. The registry record does not report a primary p-value or the hypothesis-testing procedure. It would therefore be inappropriate to infer statistical significance from the design description or from safety counts.
Why can over-dispersion matter?
As a general concept, over-dispersion occurs when observed variability is greater than a statistical model expects. If a model assumes less variability than the data contain, uncertainty can be understated and inferential results can become misleading. Methods that account for extra variability may improve uncertainty estimates when their assumptions fit the data. The registry record does not report an over-dispersion assessment or a model for the primary outcome, and the ordinal endpoint description alone does not establish that over-dispersion was relevant.
What can sample-size planning illustrations show?
Sample-size planning asks how many participants a future study might need under stated assumptions about the effect to detect, variability, significance level, allocation, and analysis. Such planning is conditional: if the assumptions are wrong, the resulting study size may not provide the anticipated precision or ability to detect the target effect. The record's stated illustration uses a two-sided significance level of 0.05, equal allocation, a normal approximation, and a target effect defined as a fraction of the observed effect. It is described as a planning illustration, not as the trial's own design justification or observed power. The registry's sample-size justification is not reported in the registry record.
Power is a design quantity describing the chance that a study would detect a specified effect under a specified model and assumptions. It is not a measure of whether a result is true, and a calculation using an observed effect after a trial is not observed power. Because the primary effect estimate is not reported in the registry record, no numerical effect-based planning result can be interpreted from the information available for this analysis.
What is not established by the registry description?
A design label and endpoint definition do not reveal the analysis model, covariate adjustment, handling of repeated or missing measurements, or sensitivity analyses. They also do not show whether the analysis followed a prespecified plan. Those details are not reported in the registry record. The absence of those details limits the ability to assess whether an eventual estimate would be robust to analytical choices, but it does not by itself establish that the methods were inappropriate.
10. Multiplicity, Missing Data and Analysis Populations
The registry lists a primary outcome and multiple secondary outcomes, including outcomes assessed at different times and outcomes based on clinical events or time to an event. Testing several outcomes can create a multiplicity issue: when many hypotheses are examined, the chance of at least one apparently notable result can increase if no adjustment or prespecified hierarchy is used. As a general statistical matter, possible approaches include adjusting significance thresholds, defining an ordered testing strategy, or treating secondary analyses as exploratory. The registry record does not report a multiplicity strategy or the statistical analysis plan.
The primary outcome is described for the mITT population, which includes randomized participants who received any amount of study medication and retains assignment at randomization for grouping. This definition is reported, but other analysis populations and their roles are not reported in the registry record. In particular, the record does not explain how the safety-evaluable populations relate to the primary analysis population.
Missing outcome data can affect an estimate if missingness is related to treatment assignment or underlying outcome. Statistical approaches may use assumptions about why data are missing, and sensitivity analyses can explore how results change under alternative assumptions. The registry record does not report the amount or pattern of missing primary-outcome data, the method used to handle missingness, or any sensitivity analyses. It is therefore not possible to assess from the record whether missingness could have influenced the primary comparison.
The record also does not report interim analyses, stopping rules, or whether any outcome definitions or analyses changed after study initiation. These matters should not be inferred from the trial's completed status.
11. Safety Results
The registry reports serious adverse events as affected participants divided by participants at risk.
| Arm | Participants with serious adverse events | Participants at risk | Percentage |
|---|---|---|---|
| Placebo Arm (Safety-Evaluable Population) | 64 | 143 | 44.8% |
| Tocilizumab (TCZ) Arm (Safety-Evaluable Population) | 116 | 295 | 39.3% |
Deaths
| Arm | Deaths (participants affected of at risk) |
|---|---|
| Placebo Arm (Safety-Evaluable Population) | 36 of 143 |
| Tocilizumab (TCZ) Arm (Safety-Evaluable Population) | 72 of 295 |
Other (non-serious) adverse events
Participants with at least one non-serious event at or above the registry's 5% reporting threshold.
| Arm | Participants affected of at risk |
|---|---|
| Placebo Arm (Safety-Evaluable Population) | 29 of 143 |
| Tocilizumab (TCZ) Arm (Safety-Evaluable Population) | 83 of 295 |
Most frequent serious adverse event terms
| Event term | Organ system | Placebo Arm (Safety-Evaluable Population) | Tocilizumab (TCZ) Arm (Safety-Evaluable Population) |
|---|---|---|---|
| COVID-19 pneumonia | Infections and infestations | 20 of 143 | 36 of 295 |
| COVID-19 | Infections and infestations | 2 of 143 | 14 of 295 |
| Septic shock | Infections and infestations | 7 of 143 | 7 of 295 |
| Acute kidney injury | Renal and urinary disorders | 4 of 143 | 10 of 295 |
| Pneumonia | Infections and infestations | 4 of 143 | 7 of 295 |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 6 of 143 | 5 of 295 |
| Cardiac arrest | Cardiac disorders | 5 of 143 | 4 of 295 |
| Pneumonia bacterial | Infections and infestations | 2 of 143 | 6 of 295 |
| Sepsis | Infections and infestations | 4 of 143 | 3 of 295 |
| Pneumothorax | Respiratory, thoracic and mediastinal disorders | 3 of 143 | 4 of 295 |
Most frequent non-serious adverse event terms
| Event term | Organ system | Placebo Arm (Safety-Evaluable Population) | Tocilizumab (TCZ) Arm (Safety-Evaluable Population) |
|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders | 10 of 143 | 17 of 295 |
| Urinary tract infection | Infections and infestations | 5 of 143 | 22 of 295 |
| Constipation | Gastrointestinal disorders | 8 of 143 | 18 of 295 |
| Hypertension | Vascular disorders | 3 of 143 | 20 of 295 |
| Diarrhoea | Gastrointestinal disorders | 3 of 143 | 18 of 295 |
| Pneumonia | Infections and infestations | 8 of 143 | 10 of 295 |
Serious events with the highest arm-level rate: covid-19 pneumonia (14.0%), septic shock (4.9%), covid-19 (4.7%), respiratory failure (4.2%), cardiac arrest (3.5%).
The safety-evaluable population is reported as 143 participants in the placebo arm and 295 in the tocilizumab arm. Serious adverse events are listed for 64 participants in the placebo group and 116 in the tocilizumab group. Other adverse events are listed for 29 and 83 participants, respectively. The reported death counts are 36 in the placebo group and 72 in the tocilizumab group. These are counts with the registry's stated denominators, not adjusted comparisons.
Counts alone do not establish a treatment effect. The group sizes differ, and the record does not provide a statistical comparison, confidence intervals, exposure-adjusted rates, or detail about the timing and duration of observation. It also does not establish whether each event was considered related to study treatment. The figures should therefore be read as descriptive registry reports rather than evidence that treatment caused or prevented events.
The listed serious adverse-event terms include COVID-19 pneumonia (14.0%), septic shock (4.9%), COVID-19 (4.7%), respiratory failure (4.2%), cardiac arrest (3.5%), and acute kidney injury (3.4%). The record does not specify a group-specific distribution for these terms in the information available for this analysis. Terms may also describe overlapping clinical events; the registry information does not clarify that issue. These percentages should not be interpreted as a comparative treatment effect or as a complete account of safety.
12. What the Result Does, and Does Not, Mean
The registry establishes that a randomized, double-blind, placebo-controlled Phase 3 study evaluated tocilizumab with standard of care against matching placebo with standard of care in hospitalized patients with severe COVID-19 pneumonia. It specifies a primary measure of clinical status at Day 28 and describes the ordered categories used to assess that status. It also records safety-evaluable group counts, event counts, deaths, and selected serious adverse-event terms.
Those details explain the study's question and some aspects of its conduct, but they do not answer the primary efficacy question. The numerical category results, group contrast, and uncertainty for the primary outcome are not reported in the registry record. Numerical results for the listed secondary outcomes are also not reported in the registry record. No conclusion about the direction, size, or precision of a clinical-status difference can be drawn from the endpoint definition alone.
The safety counts likewise have limited interpretive scope. Without a reported comparative analysis and fuller information about observation and event attribution, counts should not be treated as proof of benefit or harm caused by either study treatment. A larger count in a group does not by itself establish a higher risk, particularly when the group denominators differ. The record also does not report enough information to determine whether the groups had comparable exposure or follow-up for each safety measure.
In general, a trial result applies most directly to the participants and conditions studied, and interpretation also depends on outcome measurement, analysis choices, and the precision of estimates. Here, the record identifies a population of hospitalized patients with severe COVID-19 pneumonia, but the numerical primary findings needed to assess the comparison are not reported in the registry record. The design should not be mistaken for a result: randomization and masking strengthen the framework for comparison, but they do not reveal what the observed comparison was.
13. Why This Trial Matters Statistically
This trial is statistically notable for asking a broad clinical-status question using an ordered outcome rather than relying solely on one event category. The seven-category scale captures several levels of hospital care and respiratory support, as well as discharge and death. That structure can preserve distinctions in clinical status that would be lost if categories were collapsed. At the same time, an ordinal outcome requires careful interpretation because ordering does not imply equal spacing between categories.
The randomized, double-blind, placebo-controlled design provides a framework intended to support a fair comparison of tocilizumab plus standard care with placebo plus standard care. The mITT definition also makes explicit how the registry describes assignment and the primary analysis population. These design features are important to understand, but statistical evaluation still depends on the analysis method, missing-data handling, multiplicity strategy, and reported uncertainty. Those details are not reported in the registry record.
The record also illustrates why trial registration and trial results serve different purposes. Registration describes the intended question, design, outcomes, and population. Numerical results are needed to judge the observed effect and its precision. In this case, the primary-outcome description is available, but the numerical primary comparison is not reported in the registry record. The safety counts add descriptive information, yet do not replace an efficacy estimate or a formal comparative safety analysis.
For statisticians and clinical researchers, the key lesson is to distinguish a well-defined design from an interpretable result. The design can clarify what comparison was planned and what the endpoint represents; only outcome data and analysis details can establish the observed contrast and its uncertainty. The registry record therefore permits methodological discussion of the endpoint and design, while leaving the central numerical treatment comparison unresolved.
14. Limitations
- The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
- Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.
The central limitation for interpreting this trial from the registry record is that numerical results for the primary outcome are not reported. The record names clinical status at Day 28 and defines the scale, but does not provide the number or percentage of participants in each category by group, an effect estimate, or an uncertainty interval. Without these results, the primary randomized comparison cannot be evaluated quantitatively.
Numerical results for the listed secondary outcomes are also not reported in the registry record. This prevents assessment of whether different measures of improvement, discharge, ventilation, or intensive care provide consistent or contrasting information. The record does not state which secondary comparisons were prespecified as confirmatory, or how multiplicity was addressed.
The registry does not report the statistical model or test used for the ordinal primary endpoint, any covariate adjustment, the primary contrast, or the assumptions underlying its analysis. The method for handling missing data, the amount and pattern of missingness, and sensitivity analyses are also not reported in the registry record. These omissions limit evaluation of analytical robustness; they do not demonstrate that the trial analysis was flawed.
For safety, the record gives group denominators and counts, but does not provide comparative estimates or confidence intervals, exposure-adjusted rates, detailed follow-up information, or treatment attribution for events. The listed serious adverse-event percentages are not broken down by group in the information available for this analysis. Consequently, those figures support description but not a complete comparative safety assessment.
The record does not report the sample-size justification, interim analyses, or stopping rules. Its stated effect-based calculation is described as a planning illustration rather than the trial's own design rationale. These missing details should be treated as unreported, not reconstructed from the trial's enrollment or completion status.
15. Related Tutorials
16. Related Statistical Calculators
17. Sources
- ClinicalTrials.gov: A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia — NCT04320615.
- Registry record last updated 2021-06-30; status last verified 2021-06.
- Results first posted 2021-06-30.
- Data retrieved from ClinicalTrials.gov on 2026-11-09.
- Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.
Continue through the Clinical Biostats statistical pathway
Use this trial's endpoint as a starting point for deeper study of effect measures, confidence intervals, and sample-size planning.
18. Record Summary
NCT04320615 is a completed, randomized, double-blind, placebo-controlled, multicenter Phase 3 parallel-group study of tocilizumab plus standard of care versus matching placebo plus standard of care in hospitalized patients with severe COVID-19 pneumonia. The registry lists enrollment of 452. The tocilizumab arm could receive an intravenous dose of 8 mg/kg up to a maximum of 800 mg, with up to one additional dose permitted under specified symptom conditions.
The primary outcome is clinical status at Day 28 on a seven-category ordinal scale, assessed in the defined mITT population. The numerical primary results and secondary outcome results are not reported in the registry record. Safety-evaluable group counts and selected adverse-event figures are reported, but the record does not provide a complete comparative analysis of those events. The analysis plan, missing-data methods, multiplicity approach, and sample-size justification are not reported in the registry record.